What Laboratorios Lafedar does

Laboratorios Lafedar S.A. (doing business as Lafedar, formally Laboratorios Federales Argentinos) is an independent Argentine pharmaceutical manufacturer founded in late 1995 in Paraná, Entre Ríos. The company develops, produces, and commercializes specialty medicinal products across more than 25 therapeutic categories — including cardiology, oncology, infectious disease, gastroenterology, ophthalmology, dermatology, respiratory, endocrinology, gynecology, and pediatrics — with a portfolio of more than 600 commercializable SKUs. Production is concentrated at a single GMP-certified facility in the Parque Industrial Gral. Belgrano, equipped with robotic manufacturing technology for automated production processes, and the company has a wholly-owned oncology subsidiary, Laboratorios Oncológicos Lafedar S.A., that is currently undergoing an expansion project.

The company sells through three primary channels: (1) direct supply to Argentine provincial and national public health programs; (2) domestic pharmacy wholesale distribution; and (3) international export to more than 30 countries across Latin America, the Middle East, and Southeast Asia, executed through distribution agreements (e.g., Droguería Universal S.A. for Central America), government-to-government export agreements (Yemen Ministry of Health, June 2022), and embassy-facilitated trade relationships (Indonesia, December 2021). Named regulatory milestones include successful completion of the Yemeni Ministry of Health facility audit. Recent product launches include Crema de Bismuto Lafedar and Lurselle UD (both January 2026), and new manufacturing capacity is being built to meet higher international quality standards.

The company is privately held and founder/owner-operated, with Ricardo Guimarey, Norma Neif, and Gerónimo Guimarey identified as principals. There is no disclosed institutional investor, no public listing, and no external funding rounds in the source data. Marketing is conducted through organic social media (LinkedIn, Facebook, Instagram) and a corporate website. Pricing is not publicly disclosed and is presumed to be negotiated bilaterally in government procurement and wholesale channels. The company maintains dedicated contact channels for domestic sales ([email protected]) and international trade ([email protected]).

Name

Laboratorios Lafedar

Legal name

Laboratorios Lafedar S.A.

Website

https://lafedar.com

Company type

Private

Founded year

1995

Operating status

Operating

Headcount range

251–500 employees

Short description

Laboratorios Lafedar is an independent Argentine pharmaceutical manufacturer founded in 1995 in Paraná, Entre Ríos, producing 600+ specialty medicinal products across cardiology, oncology, infectious disease, and other therapeutic areas, and exporting to 30+ countries through government agreements and distributors.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Dermatology Specialty Pharmaceuticals (HLAIACAL)

akta.pro secondary industry

Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)

Keywords

• Pharmaceutical manufacturing
• Medicinal specialties
• Generic medicines
• Oncology drugs
• Pharmaceutical exports

Headquarters

HQ city

Parana

HQ country

Argentina

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Sale of specialty medicinal products to healthcare providers, pharmacies, and government health programs domestically and internationally.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Laboratorios Lafedar develops and manufactures medicinal specialties for human use, offering more than 600 commercializable products across multiple therapeutic categories including cardiology, oncology, respiratory, infectious diseases, gastroenterology, dermatology, ophthalmology, and gynecology. The company operates a GMP-certified production facility with robotic technology in Paraná, Entre Ríos, Argentina, and distributes its pharmaceutical products domestically through public health programs and pharmacy networks, and internationally across 30+ countries.

Product overview

Laboratorios Lafedar (Laboratorios Federales Argentinos) is an independent Argentine pharmaceutical company established in Paraná, Entre Ríos in late 1995. The company develops and manufactures medicinal specialties with over 600 commercializable products in national and international markets. The product portfolio spans multiple therapeutic categories including: Specialty products; Antivirals; Cardiology; Medical Clinic; Dermatology; Endocrinology; Gastroenterology; Gynecology; Infectious Diseases; Pulmonology; Ophthalmology; Oncology; Otolaryngology; Pediatrics; Radiology; Respiratory treatments; Special treatments; Traumatology; Over-the-counter products; Antidiarrheals; Hypoglycemics; Anti-tuberculosis; Systemic Anti-infectives; Nutrition; Metabolism; Urology; Anti-anginals; Anti-arrhythmics; Antimigraine; Antihypertensives; and Nutraceúticos. Key products include Lurselle UD (emergency contraceptive), Crema de Bismuto Lafedar (antidiarrheal), SPECTREX (antibiotic), LAFELAX (laxative), INDOMET (anti-inflammatory), DIFENAC (NSAID), CLARICINA (antibiotic), oncology products like ZALTAG, UTINIB, and ABIRATERON-A, and respiratory products like EXUDROL BUDE and TOBRAL. The company operates across more than 30 countries worldwide and has areas with robotic technology for production processes.

Differentiator

Problem solved

Functional benefit

Brands

• Lafedarnos: Social volunteerism and community outreach program
• PuenteAlTrabajo

Products and services

• Lurselle UD Emergency hormonal oral contraceptive containing Levonorgestrel 1.5 mg, presented as single-dose tablet for emergency contraception.
• Crema de Bismuto Lafedar Antidiarrheal intestinal adsorbent and topical protector of the gastrointestinal mucosa containing Bismuth and Pectin.
• SPECTREX Bactericidal chemotherapeutic agent and broad-spectrum anti-infective combining Sulfamethoxazole and Trimethoprim, available in oral suspension, injectable, and tablets.
• LAFELAX Intestinal evacuation regulator containing Lactulose 65g per 100ml, used for constipation treatment.
• INDOMET Analgesic, anti-inflammatory, and antipyretic topical cream containing Indomethacin 2g per 100g.
• DIFENAC Analgesic, anti-inflammatory non-steroidal, and antirheumatic product containing Diclofenac Sodium, available in coated tablets, suppositories, injectable, eye drops, and gel formulations.
• CLARICINA Macrolide antibiotic containing Clarithromycin available in 250mg and 500mg tablets, lyophilized injectable, and oral suspension formulations.
• FULLCAÍNA Local anesthetic containing Lidocaine with and without epinephrine, available as topical spray, injectable, and viscous topical solution.
• HASNUB Pulmonary antihypertensive containing Bosentan, available in 62.5mg and 125mg coated tablets.
• DEXALAF Corticosteroid containing Dexamethasone available in multiple dosages (0.5mg to 40mg tablets and injectables).
• ZALTAG Multiple tyrosine kinase inhibitor containing Dasatinib 50mg for oncological treatment.
• UTINIB Antineoplastic containing Imatinib (as Mesylate) in 100mg and 400mg tablets for oncological treatment.
• ABIRATERON-A Antineoplastic androgen biosynthesis inhibitor containing Abiraterone 250mg per tablet.
• TOFLAM Antibiotic and topical anti-inflammatory ophthalmic suspension containing Tobramycin and Dexamethasone.
• Lurselle UD Emergency hormonal oral contraceptive (Levonorgestrel 1.5 mg, single-dose tablet).

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Six partnerships are on record, tiered minor, core and moderate.

• Universidad Nacional de Entre Ríos (UNER) - Faculty of BromatologyminorStrategic or Co-development Partner · 14 September 2022Framework agreement for educational practices and internship programs for pharmacy students. The Faculty of Bromatology recently had its first four graduates, and the partnership aims to facilitate student insertion into the workforce.
• Ministry of Health & Population (Yemen) - Supreme Board for Drugs & Medical AppliancescoreGTM or Marketing Partner · 16 June 2022Export agreement for pharmaceutical formulations to Yemen. Successful completion of regulatory audit opens doors to Arab countries in the region.
• Instituto BecariominorStrategic or Co-development Partner · 7 April 2022Partnership under the #PuenteAlTrabajo program providing scholarships and professional internships for Industrial Engineering and Nutrition students.
• Embassy of Indonesia (Niniek Kun Naryatie, Ambassador)moderateGTM or Marketing Partner · 16 December 2021Trade relationship aimed at expanding into Southeast Asian markets. Indonesia offers access to a market of 600+ million people across 15+ countries with regional trade agreements.
• Universidad Autónoma de Entre Ríos (UADER)minorStrategic or Co-development Partner · 13 October 2021Framework agreement for internships and professional practices. Focus on connecting students with the private sector and facilitating career opportunities.
• Droguería Universal S.A. (El Salvador)minorChannel Partner/ Reseller/ Distributor · 23 January 2020Delegation visit to explore commercial partnership for distributing Lafedar products in Central American markets (Guatemala, El Salvador, Costa Rica).

Scale indicators3 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Laboratorios Bagó: One of Argentina's largest pharmaceutical manufacturers with a broad therapeutic portfolio spanning multiple specialty areas. Direct competitor to Lafedar in the Argentine domestic market and Latin American export markets, with comparable GMP manufacturing and international reach.
• Laboratorios Elea: Established Argentine pharmaceutical manufacturer with broad therapeutic coverage including oncology, gynecology, and central nervous system products. Direct competitor to Lafedar in the Argentine market with similar product breadth and government procurement focus.
• Laboratorios Richmond: Argentine pharmaceutical manufacturer with international export presence and a focus on essential medicines, including COVID-19 vaccines. Comparable to Lafedar in scale, therapeutic breadth, government procurement relationships, and international expansion ambitions.
• Roemmers: Leading Argentine pharmaceutical company with a diversified portfolio across cardiology, neurology, and other therapeutic areas. Direct competitor to Lafedar across multiple product categories in Argentina and the broader Latin American region.
• Gador: Argentine pharmaceutical company with a diversified portfolio including oncology, cardiology, and specialty therapeutic areas. Comparable to Lafedar in scale, therapeutic breadth, and positioning within the Argentine pharmaceutical industry.
• Baliarda: Argentine pharmaceutical company with a diverse product portfolio across multiple therapeutic categories. Comparable to Lafedar in size, market positioning, and therapeutic breadth within the Argentine pharmaceutical industry.

Broad incumbents

• Sandoz: Global generic and biosimilar pharmaceutical company with a broad portfolio across multiple therapeutic areas. Comparable to Lafedar in product category but operates at much larger scale globally, with established presence in emerging markets that overlap with Lafedar's expansion targets.
• Teva Pharmaceutical Industries: Global generic pharmaceutical leader with products across virtually all therapeutic areas. While much larger than Lafedar, Teva represents the same product category (generic/specialty pharmaceuticals) and competes in export markets where Lafedar operates, including Latin America and the Middle East.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/laboratorioslafedar
• LinkedInlinkedin.com/company/culturedstonebyboral
• Instagraminstagram.com/laboratorioslafedar

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Laboratorios Lafedar